# A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria

> **NCT01756703** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 67 (actual)

## Conditions studied

- Diabetic Nephropathy

## Interventions

- **DRUG:** MT-3995 Low
- **DRUG:** MT-3995 High
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01756703
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2015-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01756703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01756703, "A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01756703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*